FLU CAN BE WIDESPREAD AND EVEN DEADLY,
YET MANY REMAIN UNVACCINATED"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"4

For the 2016-2017 flu season5,*:
of adults and
of children were unvaccinated against influenza
Estimates of the percentage of people vaccinated are based on interviews conducted beginning September (BRFSS) or October (NIS-FLU) 2016 through June 2017 and reported vaccinations from July 2016 through May 2017. Excludes US territories.

If the vaccination rates were 70% (Healthy People goal) during the 2016-2017 season, vaccination could have prevented another"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"6:

  • 1.89 million illnesses
  • 822,000 medical visits
  • 17,300 hospitalizations

 

During the 2016-2017 season, vaccination successfully prevented approximately 5.29 million illnesses, 2.64 million medical visits, and 84,700 influenza-associated hospitalizations"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"6

Flu vaccination can reduce the risk of flu-associated complications among children and older adults"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"7

ADULTS*†
Unvaccinated patients aged 18+
years who were hospitalized
with the flu were
2 to 5x
MORE LIKELY TO DIE
than someone who
has been vaccinated"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"7,8
Vaccinated patients aged 18 to
49 years and 65+ years who were
hospitalized with the flu were
37%
LESS LIKELY TO BE ADMITTED
to the ICU than those
who were not unvaccinated patients"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"7,8
CHILDREN
Among children with underlying
high-risk medical conditions, vaccination
reduced the risk of flu-associated death
by 51%
and by 65%
among healthy children"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"9
BRFSS=The Behavioral Risk Factor Surveillance System.
ICU=intensive care unit.
*The data presented above are limited to patients with laboratory-confirmed influenza and those treated with antivirals, therefore these findings are not generalizable to nonhospitalized populations or whether the effects could even be more robust in a population without access to antiviral treatment.
Analysis based on 1551 adults hospitalized with laboratory-confirmed influenza from the US Influenza Hospitalization Surveillance Network (FluSurv-NET) during the 2013-14 influenza season in the United States. FluSurv-NET includes over 240 reporting hospitals, which represents approximately 9% of the US population."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"8
Case-cohort analysis based on 358 influenza-associated pediatric deaths from the National Immunization Survey–Flu (NIS-Flu), National Health Interview Survey, and the MarketScan Commercial Claims and Encounters Database (Truven Health Analytics, Ann Arbor, MI) that occurred during 4 influenza seasons from July 2010 through June 2014."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"9

Indication for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccines. FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are approved for use in persons aged 6 months and older.

Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT

  • Do not administer FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • If FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • In clinical trials with FLUARIX QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common systemic adverse reactions were muscle aches, headache, and fatigue. In children 6 through 35 months of age, the most common solicited local adverse reactions were pain and redness and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. In children 3 through 17 years of age, the solicited local adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse reactions were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events)
  • In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT may not result in protection in all vaccine recipients
 

Trademarks are property of their respective owners.

 

1008603R0 September 2018